Australia's Clarity Pharmaceuticals gains on FDA nod for cancer product trial

Clarity Pharmaceuticals

07/02/2022 02:19

** Shares of radio-pharmaceutical co  CU6.AX  jump as much
as 6.9% to A$0.770, on track for their sharpest single-day pct
gain since Jan. 28 
    ** Co says it has received confirmation from the U.S. Food
and Drug Administration for its "Cu SARbisPSMA" trial, which
covers participants with biochemical recurrence of prostate
cancer following definitive therapy  urn:newsml:reuters.com:*:nASX6yQgWF
    ** Says CU6 is headed towards registering the product in the
United States and is planning to begin recruitment for the trial
in Q2 CY2022
    ** Shares hit their highest since Jan. 31 
    ** Stock down 2.7% this year, as of last close

 (Reporting by Roushni Nair in Bengluru)
 ((Roushni.Nair@thomsonreuters.com;))